Latest biopharmaceutical Stories

LA JOLLA, Calif., Nov. 27, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Victor Knopov, Ph.D. to its executive management team as Vice President, Pharmaceutical Development. Dr. Knopov joined Regulus from Nitto Denko Technical Corporation where he served as Director, Chemistry Manufacturing Control since 2010. "Victor...

SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy. The advancement of ProHema into later-stage development...

BOSTON and TAIPEI CITY, Taiwan, Nov. 27, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) a leading global biopharmaceutical services provider, and the National Taiwan University Hospital (NTUH) announced today that they have established an alliance. Under the agreement, PAREXEL and NTUH will collaborate to provide drug development services in Taiwan. "Partnering with National Taiwan University Hospital further enhances our ability to meet the increasing demand...

HERZLIYA, Israel, November 26, 2012 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd. (TASE: PRTL) (hereinafter: "the Shares" and "Proteologics", respectively), from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (hereinafter: "Teva") in consideration for an amount of approximately NIS 6.5 million,...

The Michael J. Fox Foundation teams with UCB, Inc. to share patient stories of living with Parkinson's disease NEW YORK, Nov. 19, 2012 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has teamed up with the biopharmaceutical company UCB, Inc. to create the "Tell Us Your Story" Facebook campaign. The campaign aims to encourage members of the Parkinson's community to share their personal experience with the disease while raising dollars for...

DALLAS and NEW YORK, Nov. 15, 2012 /PRNewswire/ --ACCESS PHARMACEUTICALS, INC.(OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on MuGard commercialization activities, including progress with pharmacy benefit managers, payers and pharmacy formularies, and other new developments within the program. The investor conference call is scheduled to be held on Wednesday, November 28, 2012 at 11:00 am ET. Interested parties may...

NES-ZIONA, Israel, Nov. 13, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a patent application covering the company's long-acting reversible-pegylation technology (RPeg). Upon issuance, the new patent will provide added intellectual property protection, including additional compositions and configurations of long-acting drug product, in addition to the already-issued U.S. patent...

ST. LOUIS, Nov. 13, 2012 /PRNewswire/ -- Sigma-Aldrich(®) Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC(®) (www.safcglobal.com), has added more than 25 new raw materials to its portfolio of PharmaGrade products. Launched earlier this year, the PharmaGrade portfolio is comprised of over 65 high-quality buffers, amino acids and specialty chemicals, addressing the need for greater supply chain transparency and enhanced...

LA JOLLA, Calif., Nov. 12, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended September 30, 2012 on Monday, November 19, 2012, after the U.S. financial markets close. Regulus will host a conference call and webcast on Monday, November 19, 2012 at 5:00 pm Eastern Standard...

BURLINGAME, Calif., Nov. 11, 2012 /PRNewswire/ -- Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced today that its partner, Simcere Pharmaceutical Group (NYSE:SCR) of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801...